XOMA weakness a buying opportunity, says Piper Jaffray Piper Jaffray recommends buying shares of XOMA on weakness after the company announced that the 6-month Phase II data of gevokizumab in Erosive Osteoarthritis of the Hand failed to support further development. Piper said it had no value of this indication in its $9 price target and reiterates an Overweight rating on the name.
XOMA, Texas A&M University System agree to non-exclusive license The Texas A&M University System and XOMA announced that the Texas A&M University System agreed to a non-exclusive license for XOMA's innovative design of a manufacturing facility. The patented technology relates to an arrangement of mobile clean rooms within the manufacturing facility with each MCR providing a portable, self-contained environment that allows for drug development. The A&M System will use MCRs for certain government programs at The National Center for Therapeutics Manufacturing facility. Details of the license were not disclosed.